Segall Bryant & Hamill LLC Sells 9,439 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Segall Bryant & Hamill LLC cut its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 3.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 281,870 shares of the company’s stock after selling 9,439 shares during the quarter. Segall Bryant & Hamill LLC owned 0.17% of Option Care Health worth $9,851,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Option Care Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company’s stock worth $448,118,000 after purchasing an additional 75,313 shares in the last quarter. Wellington Management Group LLP lifted its position in Option Care Health by 84.6% in the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock worth $425,143,000 after buying an additional 8,400,208 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Option Care Health by 17.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company’s stock worth $92,518,000 after purchasing an additional 591,042 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Option Care Health by 11.8% in the fourth quarter. Northern Trust Corp now owns 2,626,478 shares of the company’s stock valued at $60,934,000 after acquiring an additional 278,158 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Option Care Health during the fourth quarter worth about $60,219,000. 98.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on OPCH. UBS Group raised Option Care Health from a “neutral” rating to a “buy” rating and upped their target price for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. JMP Securities reissued a “market outperform” rating and set a $36.00 target price on shares of Option Care Health in a research report on Wednesday, June 18th. Finally, Barrington Research reiterated an “outperform” rating and issued a $38.00 price objective on shares of Option Care Health in a research note on Thursday, July 10th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.50.

Option Care Health Price Performance

Shares of NASDAQ OPCH opened at $29.94 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.54 and a debt-to-equity ratio of 0.82. The business has a 50 day moving average price of $31.62 and a two-hundred day moving average price of $31.57. Option Care Health, Inc. has a fifty-two week low of $21.39 and a fifty-two week high of $35.53. The firm has a market cap of $4.90 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 1.84 and a beta of 0.73.

Option Care Health (NASDAQ:OPCH) last announced its earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The firm had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter in the previous year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 16.3% on a year-over-year basis. Sell-side analysts expect that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.